Home » The Viewpoint » Page 48

Category Archives: The Viewpoint

Ops Page for Editorials, and …Opinions

What’s in a Name?  Would ‘Carbavance’ Still Smell as Sweet?

Posted on by — No Comments ↓

Since the publication of a series of posters at ICAAC 2014, we finally know what’s hidden behind the ‘Carbavance’ name.  ‘Carbavance’ stands for the combination of meropenem with the B-lactamase inhibitor RPX7009 which The Medicines Company (TMC) inlicensed from Rempex Pharmaceuticals a few years ago.  This is the ‘Carbavance’ which Continue reading What’s in a Name?  Would ‘Carbavance’ Still Smell as Sweet?→

It’s Not a Free-Enterprise Market, Stupid!

Posted on by — No Comments ↓

The economics of developing antibacterials is a frustrating topic to address.  There are unique aspects to the antibiotic market which sets it apart from other medicines, esp. the unique societal aspects of antibiotic use which go beyond the benefit to the individual. IDSA has spoken out in various publications (“Bad Continue reading It’s Not a Free-Enterprise Market, Stupid!→

Fantastic – The 8th Edition of Mandell’s is Here!

Posted on by — No Comments ↓

It has grown with each edition, in page numbers, in weight, in numbers of contributors, diseases and pathogens described, and in complexity, with online access and search capabilities. More than most other therapeutic areas, the science of ID has grown in the past decades, thanks to advances in genetics, diagnostics Continue reading Fantastic – The 8th Edition of Mandell’s is Here!→